Charles S. Berkman
Known title: SVP, Gen. Counsel & SecretaryCIK: 0001392266
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ligand Pharmaceuticals Releases Q2 2026 Earnings Call Transcript. Ligand Pharmaceuticals has published the full transcript of its second-quarter 2026 earnings call, providing investors with detailed management commentary on recent performance. While the stock currently trades near a key support level, the release of this transcript offers a deeper look into the company's operational updates and strategic outlook beyond the headline financial figures.
Transaction History
| OABI | ▲ Buy | Option Exercise | 13,542 | $0 | 4/7/2026 | View on chart |
| OABI | ▼ Sell | Open Market | 7,157 | $11K | 4/7/2026 | View on chart |
| OABI | ▲ Buy | Option Exercise | 18,750 | $0 | 2/18/2026 | View on chart |
| OABI | ▼ Sell | Open Market | 9,673 | $17K | 2/18/2026 | View on chart |
| OABI | ▼ Sell | Open Market | 6,990 | $12K | 2/17/2026 | View on chart |
| OABI | ▲ Buy | Option Exercise | 13,542 | $0 | 2/16/2026 | View on chart |
| OABI | ▼ Sell | Open Market | 8,044 | $16K | 12/8/2025 | View on chart |
| OABI | ▲ Buy | Option Exercise | 15,621 | $0 | 12/7/2025 | View on chart |
| OABI | ▲ Buy | Option Exercise | 13,542 | $0 | 4/7/2025 | View on chart |
| OABI | ▼ Sell | Open Market | 7,206 | $14K | 4/7/2025 | View on chart |
| OABI | ▼ Sell | Open Market | 7,255 | $27K | 2/19/2025 | View on chart |
| OABI | ▼ Sell | Open Market | 8,215 | $30K | 2/18/2025 | View on chart |
| OABI | ▲ Buy | Option Exercise | 13,541 | — | 2/16/2025 | View on chart |
| OABI | ▲ Buy | Option Exercise | 15,615 | — | 2/15/2025 | View on chart |
| OABI | ▼ Sell | Open Market | 25,489 | $83K | 1/21/2025 | View on chart |
| OABI | ▲ Buy | Grant | 45,294 | $0 | 1/17/2025 | View on chart |
| OABI | ▼ Sell | Open Market | 8,022 | $33K | 12/9/2024 | View on chart |
| OABI | ▲ Buy | Option Exercise | 15,621 | — | 12/7/2024 | View on chart |
| OABI | ▼ Sell | Open Market | 6,954 | $37K | 4/8/2024 | View on chart |
| OABI | ▲ Buy | Option Exercise | 13,541 | — | 4/7/2024 | View on chart |
| OABI | ▲ Buy | Option Exercise | 5,698 | — | 2/15/2024 | View on chart |
| OABI | ▼ Sell | Tax Withholding | 2,034 | $11K | 2/15/2024 | View on chart |
| OABI | ▲ Buy | Option Exercise | 15,624 | — | 2/15/2024 | View on chart |
| OABI | ▼ Sell | Tax Withholding | 5,575 | $31K | 2/15/2024 | View on chart |
| OABI | ▲ Buy | Option Exercise | 17,556 | — | 1/2/2024 | View on chart |
| OABI | ▼ Sell | Tax Withholding | 7,195 | $45K | 1/2/2024 | View on chart |
| OABI | ▲ Buy | Option Exercise | 15,622 | — | 12/7/2023 | View on chart |
| OABI | ▼ Sell | Tax Withholding | 5,403 | $26K | 12/7/2023 | View on chart |
| OABI | ▲ Buy | Grant | 40,625 | $0 | 4/7/2023 | View on chart |
| OABI | ▼ Sell | Tax Withholding | 1,973 | $7K | 2/15/2023 | View on chart |
| OABI | ▼ Sell | Tax Withholding | 5,404 | $21K | 2/15/2023 | View on chart |
| OABI | ▼ Sell | Tax Withholding | 2,166 | $8K | 2/15/2023 | View on chart |
| OABI | ▲ Buy | Grant | 46,864 | $0 | 1/3/2023 | View on chart |
| OABI | ▼ Sell | Tax Withholding | 6,518 | $24K | 12/28/2022 | View on chart |
| OABI | ▼ Sell | Tax Withholding | 10,580 | $35K | 12/1/2022 | View on chart |
| LGND | ▼ Sell | Other | 11,944 | — | 11/1/2022 | View on chart |
| OABI | ▲ Buy | Grant | 353,716 | — | 11/1/2022 | View on chart |
| LGND | ▲ Buy | Grant | 5,375 | $0 | 6/10/2022 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 368 | $46K | 2/15/2022 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 633 | $78K | 2/15/2022 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 577 | $71K | 2/15/2022 | View on chart |
| LGND | ▲ Buy | Grant | 2,401 | $0 | 1/26/2022 | View on chart |
| LGND | ▲ Buy | Grant | 3,836 | $0 | 1/26/2022 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 830 | $94K | 1/26/2022 | View on chart |
| LGND | ▼ Sell | Tax Withholding | 1,326 | $151K | 1/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
OmniAb (OABI) Shares Analyst/Investor Day Slideshow
OmniAb released a slideshow from its recent Analyst/Investor Day on Seeking Alpha. The presentation offered updates on the company's pipeline and strategic plans. The material provides investors with additional detail that may influence expectations, especially as the stock trades near its recent support level of $1.48 and below the average analyst target of $8.40.
OmniAb (OABI) Shares Analyst/Investor Day Slideshow. OmniAb released a slideshow from its recent Analyst/Investor Day on Seeking Alpha. The presentation offered updates on the company's pipeline and strategic plans. The material provides investors with additional detail that may influence expectations, especially as the stock trades near its recent support level of $1.48 and below the average analyst target of $8.40.